Omni Medsci, Inc. v. Fossil et al.

This patent infringement litigation, Omni Medsci, Inc. v. Fossil et al., was initiated by Omni Medsci, Inc., a patent assertion entity (PAE) or non-practicing entity (NPE). Omni Medsci was formed in Michigan in 2010 and is part of a group of companies that commercialize optical technology invented by its founder, Dr. Mohammed N. Islam, a tenured Professor at the University of Michigan. Omni Medsci does not manufacture or sell products itself but seeks to license its patent portfolio. The defendants are major consumer electronics companies: Fossil, a global designer and manufacturer of smartwatches and wearable technology; OnePlus, known for its smartphones and smartwatches; Oura Health, a Finnish health technology company specializing in smart rings; and Samsung, a dominant player in the global wearables market, including its Galaxy Watch and Galaxy Ring products.

The complaint alleges that the defendants' wearable devices, including smartwatches and smart rings, and their associated smartphones and tablets, infringe Omni Medsci's patents by measuring physiological parameters and wirelessly transmitting the collected data. The primary patent at issue, as specified, is US Patent 11,160,455, which broadly relates to systems and methods for measuring physiological parameters using a wearable device, with details in related PTAB filings suggesting applications in reflectance pulse oximetry. While the prompt focused on the '455 patent, Omni Medsci has asserted a total of five patents in this case, all naming Dr. Islam as the sole inventor. The '455 patent is asserted against Fossil, OnePlus, and Samsung, but not Oura Health.

The case is proceeding in the Eastern District of Texas under Judge James Rodney Gilstrap. This venue is frequently chosen by patent plaintiffs, including NPEs, due to its historically efficient dockets and favorable procedural rules for patent holders. The litigation is notable for targeting multiple prominent companies in the competitive and rapidly expanding wearable technology market. Omni Medsci has a history of patent assertions, including prior litigation against Apple, where its standing to sue was upheld by the Federal Circuit despite initial challenges related to Dr. Islam's university employment. Furthermore, the case features significant parallel proceedings, with multiple inter partes reviews (IPRs) and post-grant reviews (PGRs) having been instituted against the asserted patents by the Patent Trial and Appeal Board (PTAB), including against the '455 patent. These PTAB challenges could significantly impact the district court litigation by potentially invalidating or narrowing the asserted patent claims.

Here are the key legal developments and outcomes for the patent infringement litigation Omni Medsci, Inc. v. Fossil et al., Case No. 2:24-cv-01070:

Chronological Legal Developments:

• 2024-12-20: Case Filing & Initial Pleadings

  • Omni Medsci, Inc. filed its Original Complaint against Fossil, OnePlus, Oura Health, and Samsung in the Eastern District of Texas. The initial complaint asserted infringement of five patents: U.S. Patent Nos. 9,055,868; 9,651,533; 10,517,484; 10,874,304; and 11,160,455.
  • On the same day, Fossil Group, Inc., Fossil Stores I, Inc., and Fossil Partners, L.P. filed a Sealed Motion for Summary Judgment of Noninfringement (Dkt. 3). However, given the early stage of the litigation, this may have been a placeholder or an unusual early filing.

• 2025-03-06: First Amended Complaint

  • Omni Medsci filed its First Amended Complaint (Dkt. 25), additionally asserting infringement of the U.S. Patent No. 12,193,790.

• 2025-05-19: Second Amended Complaint

  • Omni Medsci filed its Second Amended Complaint (Dkt. 57), additionally asserting infringement of the U.S. Patent No. 12,268,475.
  • Defendants Samsung, Fossil, and Oura either timely filed their answers or a motion to dismiss. Oura Health OY notably filed a Motion to Dismiss Plaintiff's Amended Complaint (Dkt. No. 68).

• 2025-08-12: Third Amended Complaint

  • Omni Medsci filed its Third Amended Complaint (Dkt. 80).
  • OnePlus had not appeared in the case as of August 27, 2025, and its answer was due by September 18, 2025.

• 2025-08-27: Motion to Stay Pending PTAB Review

  • Defendants Samsung, Fossil, and Oura Health filed a Motion to Stay Pending Institution of Inter Partes Review (IPR) and Post Grant Review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB). At this point, no depositions had been taken, fact discovery was set to close in March 2026, and the Markman hearing was scheduled for February 2026.

• 2025-08-29: Denial of Motion to Stay

  • The district court denied the defendants' Motion to Stay. The court noted that PTAB institution decisions were expected by February 12, 2026, which was before the scheduled Markman hearing and the close of fact discovery.

• 2025-10-22: Related PTAB Filings (WHOOP Case)

  • In a related case, Omni Medsci, Inc. v. WHOOP, Inc. (D. Del. Case No. 1:25-cv-00140), WHOOP, Inc. also moved to stay pending PTAB reviews, referencing numerous IPRs and PGRs filed by both WHOOP and the Samsung defendants against the same portfolio of patents, including U.S. Patent No. 11,160,455 (IPR2025-01252).

• 2025-10-XX: Claim Construction Process Begins

  • Claim construction exchanges were scheduled to begin in October 2025.
  • By November 11, 2025, both Omni MedSci and the Samsung/Fossil/Oura defendants had filed their P.R. 4-2 Disclosures of Preliminary Claim Constructions and Extrinsic Evidence, indicating the claim construction process was active.

• 2025-12-01: PTAB Institution Denials

  • The Director of the USPTO issued decisions denying institution for several IPR proceedings (IPR2025-01095, IPR2025-01100, IPR2025-01120, IPR2025-01213, IPR2025-01249) on discretionary grounds, citing the Revvo Technologies decision. These IPRs likely pertained to other patents asserted in this or related Omni Medsci litigations.

• 2026-02-02: PTAB Institution Granted for Patent 11,160,455

  • For U.S. Patent No. 11,160,455, the Patent Trial and Appeal Board (PTAB) granted institution of Inter Partes Review (IPR2025-01252). This means a formal review of the patent's validity is ongoing at the PTAB.

• 2026-02-13: Markman Hearing Scheduled

  • The Markman hearing (claim construction hearing) in the district court was scheduled for this date. No specific outcome for this hearing is detailed in the provided information.

• 2026-03-XX: Fact Discovery Closes

  • Fact discovery was scheduled to close in March 2026.

• Present Posture (2026-05-27): Active Litigation with Parallel IPR

  • The case remains active in the Eastern District of Texas. A trial is scheduled for August 17, 2026.
  • Despite the district court's denial of a stay motion pending IPR institution, an IPR challenging U.S. Patent No. 11,160,455 (IPR2025-01252) has since been instituted and is currently ongoing at the PTAB.
  • Other patents asserted by Omni Medsci in this and prior litigations have a history of PTAB challenges, with some claims being canceled (e.g., claims of '533 patent) or found unpatentable ('484 patent).

Elizabeth M. Chiaviello of Nixon Peabody LLP Identified as Counsel for Omni Medsci, Inc.

In the ongoing patent infringement case Omni Medsci, Inc. v. Fossil et al. (Case No. 2:24-cv-01070) in the Eastern District of Texas, Elizabeth M. Chiaviello has been identified as counsel for the plaintiff, Omni Medsci, Inc..

Details on Elizabeth M. Chiaviello:

• Name: Elizabeth M. Chiaviello
• Role: Counsel (appears to be a primary counsel given her participation in a certificate of conference for the plaintiff).
• Firm: Nixon Peabody LLP
• Office Location: Washington, D.C.
• Relevant Patent Litigation Experience: Ms. Chiaviello is counsel in Nixon Peabody's Intellectual Property practice group, specializing in complex intellectual property and litigation matters, including patent, trademark, and trade secret disputes. She has significant experience litigating in U.S. federal district courts and the International Trade Commission. Notably, she previously served as a law clerk to Judge Robert W. Schroeder III and Judge K. Nicole Mitchell in the Eastern District of Texas, providing her with direct experience in the court where this case is being heard. She was also recognized as "Ones to Watch" for Commercial Litigation and Intellectual Property by The Best Lawyers in America® in 2024 and a "Rising Star" by Texas Super Lawyers (2019–2023).

Further details on other potential counsel of record for Omni Medsci, Inc. in this specific case were not explicitly found in the available public search results. While past related litigation for Omni Medsci has involved other firms and attorneys (e.g., Brooks Kushman P.C. in earlier cases against Apple), current appearances for the plaintiff in 2:24-cv-01070 were only clearly identified for Ms. Chiaviello.

In the patent infringement case Omni Medsci, Inc. v. Fossil et al. (2:24-cv-01070), the defendants are represented by a combination of in-house and outside counsel. While comprehensive details for every defendant's counsel in this specific case are not fully public or explicitly detailed in all search results, information from related cases and general firm specializations provides insights into the likely legal teams.

Here's an overview of the identified counsel for the defendants:

For Oura Health:

• Firm: Mayer Brown LLP

  • Attorneys:
    • James A. Fussell, III (Partner, Washington, DC). Fussell was also part of the Mayer Brown trial team that secured a significant victory for Pantech against OnePlus in the Eastern District of Texas, where the jury found willful infringement of five patents.
    • Jasjit S. Vidwan (Counsel, Washington, DC - admitted pro hac vice in this case). Vidwan was also part of the ArentFox Schiff team that successfully represented Oura in an ITC investigation.
    • Amanda E. Stephenson (Associate, Washington, DC)
    • Angeline L. Premraj (Associate, Washington, DC). Premraj also participated in a conference with counsel for Samsung, Fossil, and Omni regarding a motion to stay.
    • Paul Choi (Partner, Washington, DC - admitted pro hac vice in this case)
    • Robert G. Pluta (Partner, Chicago, IL)
  • Relevant Experience: Mayer Brown has represented Oura Health in other patent litigation matters, including the Omni MedSci case, and has a strong track record in patent infringement suits.

• Firm: Potter Minton, PC (Local Counsel)

  • Attorney: Shaun William Hassett (Tyler, TX)

• In-house Counsel (Oura Health):

  • Kristin Lamb (Associate General Counsel, VP of Intellectual Property and Regulatory Compliance). Lamb leads an international team focused on IP development, protection, and enforcement.
  • Sonali Shah (IP Counsel). Shah specializes in protecting innovations in various technological areas, including biotech, AI, and computer science, with a background in biochemical engineering.
  • Relevant Experience: Oura Health has been actively involved in patent enforcement and defense, including a successful ITC investigation where ArentFox Schiff represented them.

For Samsung:

• In-house Counsel (Samsung Electronics America / US IP Center):
  • Tim Jezek (Principal Legal Counsel). Jezek focuses on IP litigation and related policy issues.
  • Phillip Lee (Principal Legal Counsel). Lee is a veteran litigator with experience in patent litigation, prosecution, and licensing across a wide array of technologies. He manages patent cases with outside counsel.
  • Matthew Bathon (Principal Legal Counsel). Bathon coordinates Samsung's ITC and district court dockets.
  • Relevant Experience: Samsung has a large in-house IP legal team and actively manages extensive patent litigation dockets.
• Outside Counsel (likely firms based on past Samsung patent litigation in EDTX):
  • Williams & Connolly LLP: This firm has successfully represented Samsung in patent litigation, securing dismissals.
    • Examples of attorneys from past cases: Adam Harber, Daniel Shanahan, Samuel Ford.
  • DLA Piper: This firm has secured victories for Samsung in the Eastern District of Texas, including overturning jury verdicts in patent infringement cases.
    • Examples of attorneys from past cases: Sean Cunningham, Erin Gibson (Washington, DC), Erik Fuehrer, Mark Fowler (Palo Alto), Brian Erickson (Austin).
  • McKool Smith: McKool Smith has secured significant patent infringement verdicts against Samsung. While they have represented plaintiffs against Samsung, they are a prominent patent litigation firm in EDTX and may be involved in defense for other cases.
  • Caldwell Cassady & Curry: This firm has successfully represented plaintiffs against Samsung in the Eastern District of Texas, securing large patent infringement verdicts.

For Fossil:

• Outside Counsel (likely firms based on past Fossil patent litigation):
  • Fish & Richardson P.C.: This firm represented Fossil Group in a patent infringement case that ended in a joint stipulated dismissal with prejudice, indicating a strong defense posture.
    • Examples of attorneys from past cases: David Brandon Conrad, Lance E.

For OnePlus:

• Outside Counsel (likely firms based on past OnePlus patent litigation in EDTX):
  • Leydig, Voit & Mayer: This firm has represented OnePlus in past patent appeals.
    • Example of attorney from past cases: David M. Airan.
  • Sheppard Mullin Richter & Hampton: This firm represented OnePlus in a previous patent infringement suit in the Western District of Texas that was dismissed.
  • BakerHostetler: This firm has been involved in cases concerning service of process on OnePlus.
• In-house IP Team (OnePlus Technology (Shenzhen) Co., Ltd.):
  • Mr. Xiao (Senior Member of the IP team, involved in patent licensing and litigation).
  • Ms. Zhu (IP Director).
  • Mr. Huang (Head of the IP litigation sub-team).
  • Relevant Experience: OnePlus has an in-house IP group actively involved in licensing and litigation.

It's important to note that OnePlus had not appeared in the Omni Medsci case as of August 27, 2025, and their answer was due on September 18, 2025. Therefore, specific counsel for OnePlus in this particular case might not be fully established in the public record yet if their appearance occurred after the last available detailed docket entries from the search. However, the firms and in-house counsel listed above represent their typical legal representation in patent litigation.